Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Vermont |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000232 |
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
Condition | Intervention | Phase |
---|---|---|
Opioid-Related Disorders |
Drug: Buprenorphine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Placebo Control, Crossover Assignment |
Official Title: | Alternate Day Buprenorphine Administration, Phase IX |
Ages Eligible for Study: | 22 Years to 51 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Vermont | |
Treatment Research Center | |
Burlington, Vermont, United States, 05401 |
Principal Investigator: | Warren Bickel, Ph.D. | University of Vermont |
Study ID Numbers: | NIDA-06969-14, R01-06969-14 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000232 |
Health Authority: | United States: Federal Government |
Buprenorphine Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Opioid-Related Disorders |
Sensory System Agents Therapeutic Uses Narcotic Antagonists Physiological Effects of Drugs Central Nervous System Depressants Narcotics |
Peripheral Nervous System Agents Analgesics Central Nervous System Agents Pharmacologic Actions Analgesics, Opioid |